Recombinant viral vectors and compositions that include them for use as vehicles to induce an immunological response. Multivalent viral vectors may be used in compositions or vaccines containing one or more recombinant viral vectors for protection against a variety of pathogens. Formation of these viral vectors may include insertion and expression of foreign genes to protect against a variety of pathogens. Further provided are methods of making and using the recombinant viral vectors, as well as immunogenic compositions that include the vectors and/or antigens. In particular, immunogenic compositions may include recombinant viral vectors such as vHVT509, vHVT522, and/or vHVT523.

Recombinant viral vectors and compositions that include them for use as vehicles to induce an immunological response. Multivalent viral vectors may be used in compositions or vaccines containing one or more recombinant viral vectors for protection against a variety of pathogens. Formation of these viral vectors may include insertion and expression of foreign genes to protect against a variety of pathogens. Further provided are methods of making and using the recombinant viral vectors, as well as immunogenic compositions that include the vectors and/or antigens. In particular, immunogenic compositions may include recombinant viral vectors such as vHVT509, vHVT522, and/or vHVT523.

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention relates recombinant viruses and the uses thereof. More particularly, the invention relates to novel recombinant Marek's disease viruses encoding polypeptide(s) of interest, and their use to express or deliver such polypeptides to animals, particularly poultry. The invention is particularly suited to vaccinate poultry against avian pathogens.

The present invention relates to novel stable compressed vaccine composition comprising least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention relates to novel stable compressed vaccine composition comprising least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention generally relates to a strain of Lactobacillus probiotic bacteria and a poultry vaccine for use in the in ovo vaccination of poultry, wherein said strain and said vaccine are administered to an embryonated poultry egg. Compositions suitable for use in an in ovo vaccination protocol for poultry comprising a strain of Lactobacillus probiotic bacteria and a vaccine diluent which is suitable for the poultry vaccine to be used in said vaccination protocol are also provided, as are suitable kits for use in the invention.